|
Juvenile Myelomonocytic Leukemia
|
|
0.810 |
GeneticVariation
|
UNIPROT |
American Society of Clinical Oncology Expert Statement: collection and use of a cancer family history for oncology providers.
|
24493721 |
2014 |
|
Juvenile Myelomonocytic Leukemia
|
|
0.810 |
GeneticVariation
|
BEFREE |
In the present study, we report 2 patients with somatic mosaicism for oncogenic NRAS mutations (G12D and G12S) associated with the development of JMML.
|
22753870 |
2012 |
|
Juvenile Myelomonocytic Leukemia
|
|
0.810 |
GeneticVariation
|
UNIPROT |
Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations.
|
17332249 |
2007 |
|
Juvenile Myelomonocytic Leukemia
|
|
0.810 |
CausalMutation
|
CLINVAR |
|
|
|
|
NEVUS, EPIDERMAL (disorder)
|
|
0.800 |
GeneticVariation
|
UNIPROT |
Keratinocytic epidermal nevi are associated with mosaic RAS mutations.
|
22499344 |
2012 |
|
NEVUS, EPIDERMAL (disorder)
|
|
0.800 |
CausalMutation
|
CLINVAR |
|
|
|
|
Leukemia, Myelocytic, Acute
|
|
0.740 |
GeneticVariation
|
BEFREE |
Our results show that molecular complementarity underlies the higher frequency and significantly worse prognosis associated with <i>NPM1</i>c/<i>FLT3-ITD</i> vs <i>NPM1/NRAS-G12D-</i>mutant AML and functionally confirm the role of <i>HOXA</i> genes in NPM1c-driven AML.
|
28835438 |
2017 |
|
Leukemia, Myelocytic, Acute
|
|
0.740 |
GeneticVariation
|
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
|
melanoma
|
|
0.740 |
GeneticVariation
|
BEFREE |
Since hypoxic microenvironments select for tumor cells with diminished therapeutic response, we investigated whether hypoxia unequally increases resistance to 3-BrPA in wt p53 MelJuso melanoma harbouring (Q61L)-mutant NRAS and wt BRAF, C8161 melanoma with (G12D)-mutant KRAS (G464E)-mutant BRAF, and A549 lung carcinoma with a KRAS (G12S)-mutation.
|
27863474 |
2016 |
|
Leukemia, Myelocytic, Acute
|
|
0.740 |
GeneticVariation
|
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
|
Leukemia, Myelocytic, Acute
|
|
0.740 |
GeneticVariation
|
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
|
Leukemia, Myelocytic, Acute
|
|
0.740 |
GeneticVariation
|
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
|
Leukemia, Myelocytic, Acute
|
|
0.740 |
GeneticVariation
|
BEFREE |
To elucidate the downstream functions of activated NRAS in AML, we used a murine model that harbors Mll-AF9 and a tetracycline-repressible, activated NRAS (NRAS(G12V)).
|
25316678 |
2014 |
|
Leukemia, Myelocytic, Acute
|
|
0.740 |
GeneticVariation
|
BEFREE |
Treating recipient mice transplanted with primary Nras(G12D) AMLs with 2 potent allosteric mitogen-activated protein kinase kinase (MEK) inhibitors (PD0325901 or trametinib/GlaxoSmithKline 1120212) significantly prolonged survival and reduced proliferation but did not induce apoptosis, promote differentiation, or drive clonal evolution.
|
25361812 |
2014 |
|
melanoma
|
|
0.740 |
GeneticVariation
|
BEFREE |
In a limited validation of potentially actionable low frequency mutations, a NRAS G12D mutation in a melanoma was shown to be a false positive.
|
24885028 |
2014 |
|
Leukemia, Myelocytic, Acute
|
|
0.740 |
GeneticVariation
|
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
|
melanoma
|
|
0.740 |
CausalMutation
|
CLINVAR |
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.
|
23414587 |
2013 |
|
melanoma
|
|
0.740 |
CausalMutation
|
CLINVAR |
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.
|
23414587 |
2013 |
|
melanoma
|
|
0.740 |
GeneticVariation
|
BEFREE |
To produce a mouse model of NRAS-driven melanoma, we expressed oncogenic NRAS (NRAS(G12D)) in mouse melanocytes.
|
23303902 |
2013 |
|
melanoma
|
|
0.740 |
GeneticVariation
|
BEFREE |
At clinically informative sites, we identified seven low-frequency point mutations (0.2%-4.7%), including BRAF p.V600E (melanoma, 0.2% alternate allele frequency), KRAS p.G12V (lung, 0.6%), JAK2 p.V617F (melanoma, colon, two lung, 0.3%-1.4%), and NRAS p.Q61R (colon, 4.7%).
|
23382536 |
2013 |
|
melanoma
|
|
0.740 |
CausalMutation
|
CLINVAR |
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.
|
23414587 |
2013 |
|
Leukemia, Myelocytic, Acute
|
|
0.740 |
GeneticVariation
|
CLINVAR |
RAS mutations are frequent in FAB type M4 and M5 of acute myeloid leukemia, and related to late relapse: a study of the Japanese Childhood AML Cooperative Study Group.
|
22407852 |
2012 |
|
Leukemia, Myelocytic, Acute
|
|
0.740 |
GeneticVariation
|
CLINVAR |
Inhibiting the palmitoylation/depalmitoylation cycle selectively reduces the growth of hematopoietic cells expressing oncogenic Nras.
|
22144181 |
2012 |
|
Leukemia, Myelocytic, Acute
|
|
0.740 |
GeneticVariation
|
BEFREE |
Injecting Mx1-Cre, LSL-Nras(G12D) mice with the MOL4070LTR retrovirus causes acute myeloid leukemia that faithfully recapitulates many aspects of human NRAS-associated leukemias, including cooperation with deregulated Evi1 expression.
|
21163920 |
2011 |
|
melanoma
|
|
0.740 |
CausalMutation
|
CLINVAR |
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.
|
20130576 |
2010 |